Silver Book Fact

Drugs like bevacizumab- designed to impede the growth of blood vessels and tumors- can cost more than $100,000 per patient. 

Ubel P, Berry S, Nadler E, Bell C, et al. In A Survey, Marked Inconsistency In How Oncologists Judged Value Of High-Cost Cancer Drugs In Relation To Gains In Survival. Health Aff. 2012; 31(4): 709-717. http://content.healthaffairs.org/content/31/4/709.abstract

Reference

Title
In A Survey, Marked Inconsistency In How Oncologists Judged Value Of High-Cost Cancer Drugs In Relation To Gains In Survival
Publication
Health Aff
Publisher
Project HOPE
Publication Date
2012
Authors
Ubel P, Berry S, Nadler E, Bell C, et al
Volume & Issue
Volume 31, Issue 4
Pages
709-717
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Economic Value

Related Facts

  • Since Congress passed the National Cancer Act in 1971, the percentage of the U.S. population living with, through, or beyond a cancer diagnosis has more than tripled.  
  • According to the Pharmaceutical Research and Manufacturers of America, a medicine in development targets late-stage metastatic melanoma. The medicine contains a gene encoding antigen that may be able to…  
  • Following the current path, the prostate cancer incidence rate will increase by 75.4% (786,000) between 2003 and 2023. If an alternative path is taken, there will be 21.5% (393,000) fewer…  
  • A modest decrease of 1% in cancer mortality has been estimated to be worth $500 billion in social value.  
  • Estimated Number of Cancer Survivors in the United States From 1975 to 2012